English  |  正體中文  |  简体中文  |  Items with full text/Total items : 63246/95943 (66%)
Visitors : 4848010      Online Users : 159
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/41652

    Title: Glycine transporter-1 inhibitor, N-methyglycine (sarcosine), added to clozapine for the treatment of schizophrenia
    Authors: Lane, Hsien-yuan;Huang, Chieh-liang;Wu, Po-lun;Liu, Yi-ching;張玉坤;Chang, Yue-cune;張玉坤;Lin, Pao-yen;Chen, Po-wei;Tsai, Guochuan
    Contributors: 淡江大學數學學系
    Keywords: Glutamate;GlyT-1;N-methyl-D-aspartate;sarcosine;schizophrenia;treatment
    Date: 2006-09-15
    Issue Date: 2010-01-28
    Publisher: Elsevier
    Abstract: Background

    Agonists at the N-methyl-D-aspartate (NMDA)-glycine site (D-serine, glycine, D-alanine and D-cycloserine) and glycine transporter-1 (GlyT-1) inhibitor (N-methylglycine, or called sarcosine) both improve the symptoms of stable chronic schizophrenia patients receiving concurrent antipsychotics. Previous studies, however, found no advantage of D-serine, glycine, or D-cycloserine added to clozapine. The present study aims to determine the effects of sarcosine adjuvant therapy for schizophrenic patients receiving clozapine treatment.


    Twenty schizophrenic inpatients enrolled in a 6-week double-blind, placebo-controlled trial of sarcosine (2 g/day) which was added to their stable doses of clozapine. Measures of clinical efficacy and side-effects were determined every other week.


    Sarcosine produced no greater improvement when co-administered with clozapine than placebo plus clozapine at weeks 2, 4, and 6. Sarcosine was well tolerated and no significant side-effect was noted.


    Unlike patients treated with other antipsychotics, patients who received clozapine treatment exhibit no improvement by adding sarcosine or agonists at the NMDA-glycine site. Clozapine possesses particular efficacy, possibly related to potentiation of NMDA-mediated neurotransmission. This may contribute to the clozapine’s unique clinical efficacy and refractoriness to the addition of NMDA-enhancing agents.
    Relation: Biological Psychiatry 60(6), pp.645-649
    DOI: 10.1016/j.biopsych.2006.04.005
    Appears in Collections:[數學學系暨研究所] 期刊論文

    Files in This Item:

    File Description SizeFormat

    All items in 機構典藏 are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - Feedback